The changing burden of infectious disease in Europe

Science Translational Medicine

Volumn 3, Issue 103, 2011, Pages

  Fears, Robin ^a   Van Der Meer, Jos W M ^b   Ter Meulen, Volker ^a  

^a German Academy of Sciences Leopoldina   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE; DEVELOPING COUNTRY; DISEASE SURVEILLANCE; DRUG RESEARCH; ENVIRONMENTAL CHANGE; EUROPEAN UNION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HOST SUSCEPTIBILITY; HUMAN; INFECTION CONTROL; INFECTION SENSITIVITY; INFLUENZA A (H1N1); INTEGRATED HEALTH CARE SYSTEM; MULTIDRUG RESISTANCE; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; PUBLIC-PRIVATE PARTNERSHIP; RESOURCE ALLOCATION; VACCINE PRODUCTION; VECTOR CONTROL;

EID: 80053619044     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002556     Document Type: Note

References (38)

1. Z. Jakab, Why a burden of disease study? Euro Surveill. 12, E1-E2 (2007).
2. R. Fears, J. W. M. van der Meer, V. ter Meulen, Translational medicine policy issues in infectious disease. Sci. Transl. Med. 2, 14cm2 (2010).
3. EASAC, European health and innovation policy for infectious diseases: The view from EASAC; available at http:// www.easac.eu (2011).
4. F. A. Drobniewski, V. Nikolayevskyy, S. Hoff ner, O. Pogoryelova, D. Manissero, A. J. Ozin, The added value of a European Union tuberculosis reference laboratory network-Analysis of the national reference laboratory activities. Euro Surveill. 13, 1-7 (2008).
5. J. L. Gardy, J. C. Johnston, S. J. Ho Sui, V. J. Cook, L. Shah, E. Brodkin, S. Rempel, R. Moore, Y. Zhao, R. Holt, R. Varhol, I. Birol, M. Lem, M. K. Sharma, K. Elwood, S. J. M. Jones, F. S. L. Brinkman, R. C. Brunham, P. Tang, Wholegenome sequencing and social-network analysis of a tuberculosis outbreak. N. Engl. J. Med. 364, 730-739 (2011).
6. S. Davila, V. J. Wright, C. C. Khor, K. S. Sim, A. Binder, W. B. Breunis, D. Inwald, S. Nadel, H. Betts, E. D. Carrol, R. De Groot, P. W. M. Hermans, J. Hazelzet, M. Emonts, C. C. Lim, T. W. Kuijpers, F. Martinon-Torres, A. Salas, W. Zenz, M. Levin, M. L. Hibberd, for the International Meningococcal Genetics Consortium, Genome-wide association study identifi es variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 42, 772-776 (2010).
7. M. Walport, P. Brest, Sharing research data to improve public health. Lancet 377, 537-539 (2011).
8. J. Carlet, P. Collignon, D. Goldmann, H. Goossens, I. C. Gyssens, S. Harbarth, V. Jarlier, S. B. Levy, B. N'Doye, D. Pittet, R. Richtmann, W. H. Seto, J. W. M. van der Meer, A. Voss, Society's failure to protect a precious resource: antibiotics. Lancet 378, 369-371 (2011).
9. J. Ho, P. A. Tambyah, D. L. Paterson, Multiresistant Gramnegative infections: A global perspective. Curr. Opin. Infect. Dis. 23, 546-553 (2010).
10. K. K. Kumarasamy, M. A. Toleman, T. R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, U. Chaudhary, M. Doumith, C. G. Giske, S. Irfan, P. Krishnan, A. V. Kumar, S. Maharjan, S. Mushtaq, T. Noorie, D. L. Paterson, A. Pearson, C. Perry, R. Pike, B. Rao, U. Ray, J. B. Sarma, M. Sharma, E. Sheridan, M. A. Thirunarayan, J. Turton, S. Upadhyay, M. Warner, W. Welfare, D. M. Livermore, N. Woodford, Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597-602 (2010).
11. E. Nagy, E. Urbán, C. E. Nord, on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria, Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin. Microbiol. Infect. 17, 371-379 (2011).
12. Y. Carmeli, M. Akova, G. Cornaglia, G. L. Daikos, J. Garau, S. Harbarth, G. M. Rossolini, M. Souli, H. Giamarellou, Controlling the spread of carbapenemase-producing Gram-negatives: Therapeutic approach and infection control. Clin. Microbiol. Infect. 16, 102-111 (2010).
13. M. Paul, Cost-eff ectiveness analysis in infectious diseases. Clin. Microbiol. Infect. 16, 1705-1706 (2010).
14. M. D. Zilberberg, A. F. Shorr, Understanding costeff ectiveness. Clin. Microbiol. Infect. 16, 1707-1712 (2010).
15. B. Allegranzi, S. Bagheri Nejad, C. Combescure, W. Graafmans, H. Attar, L. Donaldson, D. Pittet, Burden of endemic health-care-associated infection in developing countries: Systematic review and meta-analysis. Lancet 377, 228-241 (2011).
16. ECDC, Multidrug resistant bacteria remain a public health issue in Europe. Statement, November 2010; available at http://www.ecdc.europa.eu (2010).
17. R. K. Aziz, V. Nizet, Pathogen microevolution in high resolution. Sci. Transl. Med. 2, 16ps4 (2010).
18. M. P. Bauer, D. W. Notermans, B. H. B. van Benthem, J. S. Brazier, M. H. Wilcox, M. Rupnik, D. L. Monnet, J. T. van Dissel, E. J. Kuijper, for the ECDIS Study Group, Clostridium di cile infection in Europe: A hospital-based survey. Lancet 377, 63-73 (2011).
19. R. Dagan, K. P. Klugman, Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect. Dis. 8, 785-795 (2008).
20. S. H. E. Kaufmann, S. K. Parida, Tuberculosis in Africa: Learning from pathogenesis for biomarker identifi cation. Cell Host Microbe 4, 219-228 (2008).
21. M. P. R. Berry, C. M. Graham, F. W. McNab, Z. Xu, S. A. A. Bloch, T. Oni, K. A. Wilkinson, R. Banchereau, J. Skinner, R. J. Wilkinson, C. Quinn, D. Blankenship, R. Dhawan, J. J. Cush, A. Mejias, O. Ramilo, O. M. Kon, V. Pascual, J. Banchereau, D. Chaussabel, A. O'Garra, An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010).
22. A. J. Stevens, J. J. Jensen, K. Wyller, P. C. Kilgore, S. Chatterjee, M. L. Rohrbaugh, The role of public-sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364, 535-541 (2011).
23. Anon, Urgently needed: New antibiotics. Lancet 374, 1868 (2009).
24. European Commission, Report on the stakeholder consultation on the Transatlantic Task Force on antimicrobial resistance; available at http://www.ec.europa.eu/ health/antimicrobial-resistance/docs/antimicrobial- cons01-report-en.pdf (2011).
25. ECDC, Meeting Report. Consultation on mosquitoborne disease transmission risk in Europe; available at http://ecdc.europa.eu/en/publications/publications/ forms/ecdc-dispform.aspx?id=635.
26. E. J. Scholte, W. Den Hartog, M. Dik, B. Schoelitsz, M. Brooks, F. Schaff ner, R. Foussadier, M. Braks, J. Beeuwkes, Introduction and control of three invasive mosquito species in the Netherlands, July-October 2010. Euro Surveill. 15, 1-4 (2010).
27. EASAC, Climate change and infectious diseases in Europe; available at http://www.easac.eu (2010).
28. J. Süss, O. Kahl, Proceedings of the IXth Jena symposium on tick-borne diseases (formerly IPS). Int. J. Med. Microbiol. 298, (Supplement 1), 3-4 (2008).
29. F. Keesing, L. K. Belden, P. Daszak, A. Dobson, C. D. Harvell, R. D. Holt, P. Hudson, A. Jolles, K. E. Jones, C. E. Mitchell, S. S. Myers, T. Bogich, R. S. Ostfeld, Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature 468, 647-652 (2010).
30. C. G. Himsworth, If a pig coughs in Mexico the whole world should hear it. Lancet Infect. Dis. 10, 511-512 (2010).
31. D. G. Streicker, A. S. Turmelle, M. J. Vonhof, I. V. Kuzmin, G. F. McCracken, C. E. Rupprecht, Host phylogeny constrains cross-species emergence and establishment of rabies virus in bats. Science 329, 676-679 (2010).
32. Institute of Medicine, Adverse eff ects of vaccines: Evidence and causality; available at http://iom.edu/Reports/ 2011/Adverse-Eff ects-of-Vaccines-Evidence-and- Causality.aspx (2011).
33. S. Black, R. Rappuoli, A crisis of public confi dence in vaccines. Sci. Transl. Med. 2, 61mr1 (2010).
34. ECDC, First European reference laboratory network for tuberculosis launched. Statement, January 2010; available at http://www.ecdc.europa.eu (2010).
35. S. Perry, H. Linton, G. Schoolnik, Tuberculosis in North Korea. Science 331, 263 (2011).
36. Royal Society, AAAS, New frontiers in science diplomacy. RS Policy document 01/10; available at http://diplomacy. aaas.org/fi les/New-Frontiers. pdf.
37. T. Pang, N. Daulaire, G. Keusch, R. Leke, P. Piot, S. Reddy, A. Rys, N. Szlezak, The new age of global health governance holds promise. Nat. Med. 16, 1181 (2010).
38. Joint G8 science academies, The role of science, technology and innovation for development in Africa and other developing regions; available at http:// www.leopoldina-halle.de/cms/en/policy-advice/ recommendations-and- statements/g8-statements. html (2010).